Literature DB >> 30460984

Exogenous IL-19 attenuates acute ischaemic injury and improves survival in male mice with myocardial infarction.

Weishuai An1, Yongsheng Yu1, Yuefan Zhang2, Zhigang Zhang3, Yunhua Yu4, Xianxian Zhao1.   

Abstract

BACKGROUND AND
PURPOSE: Myocardial infarction (MI) is one of the leading causes of death in China and often results in the development of heart failure. In this work, we tested the therapeutic role of Interleukin-19 (IL-19) in mice with MI and investigated the underlying molecular mechanism. EXPERIMENTAL APPROACH: Mice were subjected to MI by ligation of left anterior descending coronary artery (LAD) and treated with IL-19 (10ng g-1 ; i.p.). KEY
RESULTS: Protein expression of IL-19 and its receptor in myocardium were upregulated 24 hrs post-MI in male mice. IL-19 treatment decreased infarct and apoptosis in myocardium, accompanied by enhanced haem oxygenase-1 (HO-1) activities and reduced malondialdehyde (MDA) formation. Pretreatment with IL-19 upregulated HO-1 expression in cultured neonatal mouse ventricular myocytes and attenuated oxygen-glucose deprivation (OGD)-induced injuries in vitro. Furthermore, IL-19 preserved cardiac function and improved survival of mice with MI. IL-19 reduced inflammatory infiltrates and suppressed formation of TNF-α, IL-1β, and IL-6. More importantly, IL-19 inhibited polarization toward proinflammatory M1 macrophages and stimulated M2 macrophage polarization in myocardium of mice with MI. IL-19 enhanced protein levels of vascular endothelial growth factor (VEGF) and promoted angiogenesis in myocardium of mice with MI. In addition, IL-19 treatment increased DNA-binding of the transcription factor STAT3 in myocardium of mice with MI. CONCLUSIONS AND IMPLICATIONS: Treatment with exogenous IL-19 attenuated acute ischemic injury and improved survival of mice with MI. The mechanisms underlying these effects involved induction of HO-1, M2 macrophage polarization, angiogenesis, and STAT3 activation.
© 2018 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30460984      PMCID: PMC6365357          DOI: 10.1111/bph.14549

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  54 in total

1.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9.

Authors:  Ewa Zajac; Bernhard Schweighofer; Tatyana A Kupriyanova; Anna Juncker-Jensen; Petra Minder; James P Quigley; Elena I Deryugina
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

Review 3.  Heme oxygenase-1: an emerging therapeutic target to curb cardiac pathology.

Authors:  Gabor Czibik; Geneviéve Derumeaux; Daigo Sawaki; Guro Valen; Roberto Motterlini
Journal:  Basic Res Cardiol       Date:  2014-10-25       Impact factor: 17.165

4.  Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers.

Authors:  Michael J Curtis; Steve Alexander; Giuseppe Cirino; James R Docherty; Christopher H George; Mark A Giembycz; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Yong Ji; David J MacEwan; Christopher G Sobey; S Clare Stanford; Mauro M Teixeira; Sue Wonnacott; Amrita Ahluwalia
Journal:  Br J Pharmacol       Date:  2018-04       Impact factor: 8.739

5.  Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice.

Authors:  S F Yet; R Tian; M D Layne; Z Y Wang; K Maemura; M Solovyeva; B Ith; L G Melo; L Zhang; J S Ingwall; V J Dzau; M E Lee; M A Perrella
Journal:  Circ Res       Date:  2001-07-20       Impact factor: 17.367

6.  Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function.

Authors:  Xiaoli Liu; Alok S Pachori; Christopher A Ward; J Paul Davis; Massimiliano Gnecchi; Deling Kong; Lunan Zhang; Jared Murduck; Shaw-Fang Yet; Mark A Perrella; Richard E Pratt; Victor J Dzau; Luis G Melo
Journal:  FASEB J       Date:  2006-02       Impact factor: 5.191

7.  Macrophage subpopulations are essential for infarct repair with and without stem cell therapy.

Authors:  Tamar Ben-Mordechai; Radka Holbova; Natalie Landa-Rouben; Tamar Harel-Adar; Micha S Feinberg; Ihab Abd Elrahman; Galia Blum; Fred H Epstein; Zmira Silman; Smadar Cohen; Jonathan Leor
Journal:  J Am Coll Cardiol       Date:  2013-08-21       Impact factor: 24.094

Review 8.  Angiogenesis in the infarcted myocardium.

Authors:  Clement Cochain; Keith M Channon; Jean-Sébastien Silvestre
Journal:  Antioxid Redox Signal       Date:  2012-09-25       Impact factor: 8.401

9.  The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions.

Authors:  Matthias Nahrendorf; Filip K Swirski; Elena Aikawa; Lars Stangenberg; Thomas Wurdinger; Jose-Luiz Figueiredo; Peter Libby; Ralph Weissleder; Mikael J Pittet
Journal:  J Exp Med       Date:  2007-11-19       Impact factor: 14.307

10.  Systemic and Cardiac Depletion of M2 Macrophage through CSF-1R Signaling Inhibition Alters Cardiac Function Post Myocardial Infarction.

Authors:  Anne-Laure Leblond; Kerstin Klinkert; Kenneth Martin; Elizebeth C Turner; Arun H Kumar; Tara Browne; Noel M Caplice
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

View more
  8 in total

1.  Interleukin-19 Promotes Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy.

Authors:  Jingling Zou; Wei Tan; Bingyan Li; Zicong Wang; Yun Li; Jun Zeng; Bing Jiang; Shigeo Yoshida; Yedi Zhou
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-07-08       Impact factor: 4.925

Review 2.  Resolution of inflammation in immune and nonimmune cells by interleukin-19.

Authors:  Tani Leigh; Rosario G Scalia; Michael V Autieri
Journal:  Am J Physiol Cell Physiol       Date:  2020-07-15       Impact factor: 5.282

Review 3.  Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.

Authors:  Alexander E Berezin; Alexander A Berezin
Journal:  Dis Markers       Date:  2020-06-12       Impact factor: 3.434

Review 4.  Toward Regeneration of the Heart: Bioengineering Strategies for Immunomodulation.

Authors:  Arianna Ferrini; Molly M Stevens; Susanne Sattler; Nadia Rosenthal
Journal:  Front Cardiovasc Med       Date:  2019-03-21

5.  Grape Seed Proanthocyanidin Extract Ameliorates Cardiac Remodelling After Myocardial Infarction Through PI3K/AKT Pathway in Mice.

Authors:  Yongxue Ruan; Qike Jin; Jingjing Zeng; Fangfang Ren; Zuoyi Xie; Kangting Ji; Lianpin Wu; Jingguo Wu; Lei Li
Journal:  Front Pharmacol       Date:  2020-12-04       Impact factor: 5.810

6.  Recombinant Interleukin-19 Suppresses the Formation and Progression of Experimental Abdominal Aortic Aneurysms.

Authors:  Hiroki Tanaka; Baohui Xu; Haojun Xuan; Yingbin Ge; Yan Wang; Yankui Li; Wei Wang; Jia Guo; Sihai Zhao; Keith J Glover; Xiaoya Zheng; Shuai Liu; Kazunori Inuzuka; Naoki Fujimura; Yuko Furusho; Toru Ikezoe; Takahiro Shoji; Lixin Wang; Weiguo Fu; Jianhua Huang; Naoki Unno; Ronald L Dalman
Journal:  J Am Heart Assoc       Date:  2021-08-28       Impact factor: 5.501

7.  Protective Effects and Mechanisms of Recombinant Human Glutathione Peroxidase 4 on Isoproterenol-Induced Myocardial Ischemia Injury.

Authors:  Chang Liu; Bozhao Li; Qi Yan; Shaopeng Niu; Yiding Zhao; Changhao Xiong; Tianjiao Zhang; Jingyan Wei
Journal:  Oxid Med Cell Longev       Date:  2021-09-07       Impact factor: 6.543

8.  Remodelling of adult cardiac tissue subjected to physiological and pathological mechanical load in vitro.

Authors:  Fotios G Pitoulis; Raquel Nunez-Toldra; Ke Xiao; Worrapong Kit-Anan; Saskia Mitzka; Richard J Jabbour; Sian E Harding; Filippo Perbellini; Thomas Thum; Pieter P de Tombe; Cesare M Terracciano
Journal:  Cardiovasc Res       Date:  2022-02-21       Impact factor: 10.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.